Jacobio Pharma

Showing 1 posts of 1 posts found.

Jacobio Pharma receives CDE approval for pancreatic cancer study in China

July 5, 2023
Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial

Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …

Latest content